Jubilant Pharmova Limited has informed the Exchange about Schedule of meet and Presentation
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova has informed the stock exchanges that its management will hold a virtual group meeting with 8 institutional investors on August 13, 2025, organized by Nirmal Bang Institutional Equities. The list includes ASK Investment Managers, Bajaj Finserv AMC, Parag Parikh Financial Advisory Services, Karma Capital, 2Point2 Capital, Bank of India, Bay Capital, and Sundaram Alternates. The company also shared its July 2025 investor presentation as an enclosure. The presentation reveals Q1'FY26 revenue of Rs 1,901 Cr (up 10% YoY) and EBITDA of Rs 302 Cr (up 14% YoY), with the business split across Radiopharma (46%), CDMO-Sterile Injectables (19%), CRDMO (16%), Allergy Immunotherapy (10%) and Generics (9%). The company has shared its Vision 2030 targets of 2x revenue growth to Rs 13,500 Cr, 23-25% EBITDA margins, zero net debt, and high teens RoCE. Geographic mix shows 79% of revenue from the USA, with 93% of revenue in USD.
This is a routine regulatory disclosure of an investor engagement, so the immediate stock impact is likely neutral. However, the attached presentation provides detailed Q1'FY26 results, segment-level performance, and Vision 2030 guidance, which should help investors better assess growth prospects in the Radiopharma, CDMO, and Allergy Immunotherapy businesses.